Abstract: In certain embodiments, this disclosure relates to pharmaceutical formulations for polypeptide and lipophilic moiety conjugates suitable for injection into humans and other animals and methods of preparation. In certain embodiments, the disclosure relates to a method of preparing the formulation comprising lyophilizing, solubilizing in ammonium acetate, filtering to create mono-disperse particles, re-lyophilizing, and solubilizing the micelles in a dextrose solution for injection.

Abstract: Probiotic microorganisms are micro encapsulated by dispersing the probiotic microorganism in an aqueous suspension of a film forming protein and a carbohydrate; in an oil in water emulsion of a film forming protein and a carbohydrate and a fat; or in an oil which is subsequently dispersed in a film forming protein and a carbohydrate. The emulsion or suspension may be dried to form a powder. The probiotic may be dispersed in oil and then emulsified with the aqueous suspension and then dried to produce an encapsulated oil be dried to produce a powder. Oil suspended probiotics may be preferred where the probiotic is water sensitive. The preferred protein is casein or whey protein and the carbohydrate may be a resistant starch or a saccharide with a reducing sugar group. Where the probiotic is oxygen sensitive the protein carbohydrate is heated to create Maillard reaction products in the encapsulating film.

Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.

Abstract: Aureolic acid derivatives, process for obtaining them and uses thereof. This invention provides a bacterial strain that produces compound belonging to the family of aureolic acids useful in the treatment of cancer or nervous system diseases.

Abstract: The present invention provides compounds characterized by the formula (I), where each of the substituent radicals is described in the specification. The invention also describes the use of said compounds in the treatment of various diseases, including: cancer or tumoral processes in general, Paget's disease, hypercalcaemia, hypercalciuria and neurological diseases (inter alia, Parkinson's, Alzheimer's, Huntington's).

Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.

Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.

Abstract: This invention relates to a new class of polyene polyketides, their pharmaceutically acceptable salts and derivatives, and to methods for obtaining the compounds. One method of obtaining these compounds is by cultivation of novel strains of Streptomyces aizunensis; another method involves expression of biosynthetic pathway genes in transformed host cells. The present invention further relates to the novel strains of Streptomyces aizunensis used to produce these compounds, to the use of these compounds and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use as inhibitors of fungal cell growth and cancer cell growth. The invention also relates to pharmaceutical compositions comprising these novel polyketides or a pharmaceutically acceptable salts or derivatives thereof. Finally, the invention relates to novel polynucleotide sequences and their encoded proteins, which are involved in the biosynthesis of these novel polyketides.

Abstract: There is described a process for the synthesis of a fluoronucleoside compound, said process comprising mixing a substrate and an enzyme from Streptomyces cattelya as catalyst. The process may be used to produce an 18F labelled fluoronucleoside compound. There is also described an enzyme derived from Streptomyces cattelya which has the capacity to catalyse the synthesis of a fluoronucleoside compound.

Abstract: In one aspect, the present invention provides an improved method for the manufacture of Pravastatin sodium salt by fermentation under optimal fermentation parameters using a new strain of Streptomyces flavidovirens.

Abstract: An isolated gene encodes for a L-proline-3-hydroxylase having the amino acid sequence of SEQ ID NOS: 1, 2, 15, 16 and 17, or for a protein having enzymatic activity to hydroxylate the 3-position of L-proline and to act on free L-proline in the presence of 2-ketoglutaric acid and divalent iron ions to produce cis-3-hydroxy-L-proline. The gene is inserted into a vector and the resulting recombinant DNA is used to create a transformant. L-proline-3-hydroxylase is produced by culturing the transformant in a medium.

Abstract: Embodiments of the invention generally provide methods and compositions for producing recombinant transglutaminases. The purified recombinant transglutaminases of the invention are reactive to a broad range of compounds and exhibit broad substrate activity. In one embodiment, Streptoverticillium mobaraense (ATCC 29032), and Streptoverticillium cinnamoneum (ATCC 11874) recombinant transglutaminase fusion proteins purified from E. coli are provided to a better yield, higher purity, and activity than hitherto possible by recombinant DNA technology.

Abstract: This invention relates to new antibiotics designated AA-896-A1, AA-896-A2, AA-896-A3, AA-896-A4, AA-896-A5, AA-896-A6, AA-896-Bl, AA-896-B2, AA-896-B3, AA-896-B4, AA-896-B5, AA-896-B6, AA-896-B7, AA-896-C1, AA-896-C2, AA-896-C3, AA-896-C4, AA-896-C5, AA-896-D1, AA-896-D2, AA-896-D3 and AA-896-D4 derived from the microorganism Streptomyces spp. LL-AA896 which are useful an anti-bacterial agents.

Abstract: The present invention relates to novel active compounds named Citrullimycines, which are obtainable by cultivation of Streptomyces sp. ST 101396 (DSM 13309), and to their pharmaceutically acceptable salts and derivatives. The present invention further relates to a process for the production of the Citrullimycines, to the microorganism Streptomycetes sp. ST 101396 (DSM 13309), to the use of the Citrullimycines and their pharmaceutically acceptable salts and derivatives as pharmaceuticals, for example as inhibitors of the neurotensin receptor, and to pharmaceutical compositions comprising Citrullimycines or a pharmaceutically acceptable salt or derivative thereof.

Abstract: A novel method of producing PS is described herein. The method first involves producing PLD enzyme through the use of enzyme-producing microorganisms. The PLD enzyme is reacted with a lecithin and source of serine to produce the phosphatidylserine (PS). The method differs from prior methods in several ways. First, it incorporates a novel strain of PLD enzyme-producing organism in a preferred embodiment. It is also the first known PS production method that allows for the reuse of the enzyme and serine components to enhance efficiency and productivity. It further incorporates a novel solvent system, unique stabilization agents for the PLD enzyme, as well as optimized reaction conditions.

Abstract: A novel antibiotic-producing Streptomyces sp. is provided that exhibits antifungal activity only on certain specific plant pathogens. Also provided is a method of treating or protecting plants from fungal infections comprising applying an effective amount of an antibiotic-producing Streptomyces sp. having all the identifying characteristics of NRRL Accession number B-30145. The invention also relates to fungicidal compositions comprising this novel Streptomyces strain and the antibiotics and metabolites produced by this strain either alone, or in combination with other chemical and biological pesticides.

Abstract: There have been obtained, by cultivation of Streptomyces sp. MK730-62F2 (deposit number of FERM BP-7218), antibiotic caprazamycins A to F having by the following general formula (I) wherein R is tridecyl group, 11-methyl-dodecyl group, and others. These caprazamycins have excellent antibacterial activities against various acid-fast bacteria and various bacteria as well as their drug-resistant strains.

Abstract: A composition containing a peripheral benzodiazepine receptor ligand for topical use in the treatment of cutaneous stress.

Abstract: The invention discloses highly purified daptomycin and to pharmaceutical compositions comprising this compound. The invention discloses a method of purifying daptomycin comprising the sequential steps of anion exchange chromatography, hydrophobic interaction chromatography and anion exchange chromatography. The invention also discloses a method of purifying daptomycin by modified buffer enhanced anion exchange chromatography. The invention also discloses an improved method for producing daptomycin by fermentation of Streptomyces roseosporus. The invention also discloses high pressure liquid chromatography methods for analysis of daptomycin purity. The invention also discloses lipopeptide micelles and methods of making the micelles. The invention also discloses methods of using lipopeptide micelles for purifying lipopeptide antibiotics, such as daptomycin. The invention also discloses using lipopeptide micelles therapeutically.

Abstract: A method for converting organic solid waste into humic products and the corresponding apparatus, in which a preliminary aerobic fermentation of the organic solid waste is performed, followed by a second aerobic fermentation of the organic waste in the presence of specific microorganisms in order to provide a basic precursor on which the selective metabolization occurs of specific bacterial strains to provide the humic product.

Abstract: The present invention relates to a novel microorganism Streptomyces megasporus SD5. The present invention also relates to a process for the isolation of said Streptomyces megasporus SD5. The invention also relates to a novel fibrinolytic enzyme actinokinase extracted from said microorganism and to a process for the extraction of said enzyme. In another aspect, the invention also pertains to a method for the treatment of thrombolytic disorders using said enzyme.

Abstract: A process for the isolation of clavulanic acid and pharmaceutically acceptable salts thereof, such as potassium clavulanate, from the aqueous fermentation broth of a clavulanic acid-producing microorganism comprises the microfiltration of the broth without prior treatment.

Abstract: A novel antibiotic-producing Streptomyces sp. is provided that exhibits antifungal activity only on certain specific plant pathogens. Also provided is a method of treating or protecting plants from fungal infections comprising applying an effective amount of an antibiotic-producing Streptomyces sp. having all the identifying characteristics of NRRL Accession number B-30145. The invention also relates to fungicidal compositions comprising this novel Streptomyces strain and the antibiotics and metabolites produced by this strain either alone, or in combination with other chemical and biological pesticides.

Abstract: A novel antibiotic-producing Streptomyces sp. is provided that exhibits antifungal activity only on certain specific plant pathogens. Also provided is a method of treating or protecting plants from fungal infections comprising applying an effective amount of an antibiotic-producing Streptomyces sp. having all the identifying characteristics of NRRL Accession number B-30145. The invention also relates to fungicidal compositions comprising this novel Streptomyces strain and the antibiotics and metabolites produced by this strain either alone, or in combination with other chemical and biological pesticides.

Abstract: A process for production of an alkaline tolerant dextranase enzyme comprises culturing a dextran-producing microorganism Streptomyces anulatus having accession no. ATCC PTA-3866 to produce an alkaline tolerant dextranase, Dex 1 wherein the protein in said enzyme is characterized by a MW of 63.3 kDa and Dex 2 wherein its protein is characterized by a MW of 81.8 kDa.

Abstract: The present invention provides methods of making paper, utilizing glucans, produced by the glucosyltransferase B, C or D enzyme of the species Streptococcus mutans, instead of modified starches. The present glucans are functionally similar to currently utilized modified starches and are particularly useful in the coating step of paper manufacture. The present glucans also exhibit thermoplastic properties and impart gloss to the paper during the coating step.

Abstract: Lichen-derived organic acids such as vulpinic acid and usnic acid have been found to be effective inhibitors of eukaryotic protein kinase activity. Thus, eukaryotic protein kinase activity present in a sample or organism can be inhibited by adding to the sample or organism an effective inhibitory amount of a lichen-derived organic acid.

Abstract: A purified amino alcohol dehydrogenase which reductively converts a keto alcohol into an amino alcohol and oxidatively converts an amino alcohol into a keto alcohol is disclosed. The enzyme is NAD(H) dependent, has a molecular weight of 100,000 Da when determined by gel filtration, has a optimum temperature of about 30° C. in reductive amination, an optimum pH of 10.0 in an oxidative deamination and of 7.0 in a reductive amination and can be isolated from Steptomyces virginiae.

Abstract: The present invention relates to a compound named Mumbaistatin, its pharmaceutically acceptable salts and derivatives, a process for its production, and its use as a pharmaceutical. Mumbaistatin is obtainable by cultivation of the microorganism HIL-008003 (DSM 11641). Mumbaistatin is a glucose-6-phosphate translocase inhibitor and can be used in the treatment of diabetes mellitus. The present invention further relates to a process for the production of Mumbaistatin, to the microorganism HIL-008003 (DSM 11641), to the use of Mumbaistatin and its pharmaceutically acceptable salts and derivatives as pharmaceuticals, in particular to their use in the treatment of diabetes mellitus, and to pharmaceutical compositions comprising Mumbaistatin or a pharmaceutically acceptable salt or derivative thereof.

Abstract: The present invention provides methods of making paper, utilizing glucans, produced by the glucosyltransferase B, C or D enzyme of the species Streptococcus mutans, instead of modified starches. The present glucans are functionally similar to currently utilized modified starches and are particularly useful in the coating step of paper manufacture. The present glucans also exhibit thermoplastic properties and impart gloss to the paper during the coating step.

Abstract: The present invention relates to antifungal biocontrol agents which enhance plant growth and reduce plant diseases by suppressing fungal pathogens, and the manufacturing and application methods thereof. The antifungal biocontrol agents of the present invention consist of one of the newly isolated strains of Streptomyces sp. WYE 20 (KCTC 0341BP) and WYE 324 (KCTC 0342BP) and a delivery medium which canies and stabilizes the cells. In particular, WYE 20 and WYE 324 of the present invention exhibit strong antifungal activity against Rhizoctonia solani and Phytophthora capsici and can be used in various ways to reduce fungal diseases in plants such as cucumber (Cucumis sativus L.), pepper (Capsicum annuum L.), and golf course turfgrasses.

Abstract: Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.

Abstract: A process for the isolation of clavulanic acid and pharmaceutically acceptable salts thereof, such as potassium clavulanate, from the aqueous fermentation broth of a clavulanic acid-producing microorganism comprises the microfiltration of the broth without prior treatment.

Abstract: Lichen-derived organic acids such as vulpinic acid and usnic acid have been found to be effective inhibitors of eukaryotic protein kinase activity. Thus, eukaryotic protein kinase activity present in a sample or organism can be inhibited by adding to the sample or organism an effective inhibitory amount of a lichen-derived organic acid.

Abstract: One or more identified biologically pure strains of Actinomycete isolated from ATCC 55984 and methods of using the strains. The strains are used to confer protection against plant pathogen infection in a susceptible plant and are also used to enhance growth in a responsive plant. The methods of use include contacting at least a plant part, soil or soil-less potting mixture with a composition that includes at least one of the identified strains of Actinomycetes.

Abstract: This invention relates to Streptomyces avermitilis lacking branched-chain amino acid transaminase activity, branched-chain 2-oxo acid biosynthetic activity and, optionally and preferably, avermectin B-O-methyl transferase activity, methods for preparation thereof, and use thereof to produce natural and non-natural avermectins from branched-chain fatty acid or branched-chain 2-oxo acid precursors. Such avermectins are useful as parasiticides.

Abstract: A batch fermentation is carried out continuously or semicontinuously using strain of Streptomyces clavuligerus for the production of clavulanic acid. The fermentation process is carried out with strict control of the soluble phosphate in the medium both at the beginning and throughout the process.

Abstract: The present invention is directed to methods and compositions for biological control of plant diseases using suppressive avirulent strains of Streptomyces spp. to control disease on a vegetable or other susceptible crop. The method includes applying one or more naturally occurring, suppressive avirulent strains of Streptonmces spp. to the crop to inhibit the growth of Streptomyces scabies or other plant pathogenic organisms that cause scab, wilt, or seedling blight disease. Preferably, at least two suppressive avirulent strains of Streptomyces spp. are applied to reduce the change of resistance from occurring. The suppressive avirulent strains ame compatible and will grow in the presence of one another and, when combined with the pathogenic organism, at least one of the suppressive avirulent strains preferably substantially outgrows the pathogen.

Abstract: A microorganism belonging to the genus Staphylococcus or the genus Streptomyces which is capable of degrading a polylactic acid resin. A method of degrading a polylactic acid resin including a step of culturing a microorganism capable of degrading a polylactic acid resin in a medium containing a polylactic acid resin. In particular, the microorganisms Streptomyces violaceusniger FERM BP-6110 and Streptomyces cyaneus FERM BP-6111 are used.

Abstract: An enzymatic hydroxylation process for the preparation of compounds useful as HMG-CoA reductase inhibitors and/or as intermediates in the preparation of HMG-CoA reductase inhibitors uses a microorganism or an enzyme derived from, or having the structure of an enzyme derived from, said microorganism, which is capable of catalyzing the hydroxylation process.

Abstract: A process for the isolation of clavulanic acid pharmaceutically acceptable salts thereof, such as potassium clavulanate, from the aqueous fermentation broth of a clavulanic acid-producing microogranism comprises the microfiltration of the broth without prior treatment.

Abstract: Improved methods for the preparation of clavams by fermentation of a clavam-producing organism in a suitable medium wherein the ammonium levels are kept low so as to avoid repression of enzymes, particularly urease, are disclosed.

Abstract: The present invention relates to a method of preparing a variant of a parent lipolytic enzyme, comprising (a) subjecting a DNA sequence encoding the parent lipolytic enzyme to random mutagenesis, (b) expressing the mutated DNA sequence obtained in step (a) in a host cell, and (c) screening for host cells expressing a mutated lipolytic enzyme which has a decreased dependance to calcium and/or an improved tolerance towards a detergent or a detergent component as compared to the parent lipolytic enzyme.

Abstract: An acidic polycyclic ether antibiotic, having structure established by X-ray crystallography, is formed by fermentation of a novel microorganism, Streptomyces sp. ATCC 55028. This novel antibiotic is useful as an anticoccidial in chickens, in the prevention or treatment of swine dysentery, as a growth promotant in cattle and swine, and as an anthelmintic in mammals, particularly in dogs, cats, sheep, cattle and swine.

Abstract: The present invention relates to chrolactomycin compound represented by the following formula (I): ##STR1## or pharmaceutically acceptable salts thereof having antibacterial and antitumor activities.

Abstract: Novel polyene antibiotics, 3874 H1 to H6, processes for their preparation and use which are suitable for treating fungal diseases, trichomonad diseases, and for treating diseases associated with an increased steroid concentration.

Abstract: A process for the microbiological or enzymatic hydrolytic resolution of racemic trans-2-(alkoxycarbonylethyl) lactams of the formula I: ##STR1## wherein R is C.sub.1 -C.sub.7 alkyl, 2,2,2-trifluoroethyl or methoxyethoxyethyl and R.sup.1 is hydrogen or a protecting group is disclosed, whereby an optically enriched compound of the formula Ib or IIa: ##STR2## is obtained.

Abstract: A process for separating a natural B avermectin from a natural avermectin containing fermentation broth by using an aqueous precipitation. The process comprises extracting natural avermectins from the fermentation broth with a water miscible solvent and adding sufficient water to precipitate the natural B avermetins. Preferably, the water miscible solvent is a C.sub.1 -C.sub.3 alcohol, acetone, or acetonitrile. In addition, an acid, base, salt or surfactant may be added to facilitate the precipitation. This invention provides an isolation technique that substitutes the use of an aqueous precipitation for nonaqueous solvent precipitations. The reduction in use of nonaqueous solvents provides economic, environmental and safety benefits.

Abstract: A method of removing color from wood pulp is disclosed. The method comprises the steps of preparing a wood pulp, treating the wood pulp with the xylanase wherein the xylanase is capable of releasing chromophores from the pulp and extracting the wood pulp to remove chromophores. Also disclosed are substantially purified preparations of xylanase enzymes from bacterial isolates.

Abstract: A microbiological assay for chemicals, which uses a cell and a reducing dye to quantitatively measure inhibition of electron transport in the cell membrane as a function of chemicals in the substance being tested, is disclosed. This assay and method is reliable, simple, fast, and inexpensive, requires a minimum amount of durable equipment, and avoids the need for the use of live animals as the indicator organisms. The assay is particularly useful for testing for toxicity in food products, environmental, medical and industrial processes, sewage treatment, effluent, agricultural wastes, and chemical dumps.